Arbutus to Participate in Upcoming Investor Conferences

On May 26, 2021 Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), reported that the Company will participate in the following upcoming investor conferences (Press release, Arbutus Biopharma, MAY 26, 2021, View Source [SID1234580597]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Healthcare Conference

Wednesday, June 2, 2021 at 9:00 am ET (Fireside Chat)
Presenters: William Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer
Webcast Link
JMP Securities Life Sciences Conference – Virtual

Thursday, June 17, 2021 at 11:00 am ET (Fireside Chat)
Presenters: William Collier; Dr. Michael Sofia; Dr. Gaston Picchio; and David Hastings
Webcast Link
The webcast links for the virtual fireside chats can also be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com. An archived replay of the webcast will be available on the Company’s website after the conference.